Please refer attached file

14th September, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai - 400 051 BSE scrip code: 543635 NSE Symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) – FDA Inspection Dear Sir / Madam, This is to inform you that the US FDA conducted Good Manufacturing Practices (GMP) inspection of Piramal Pharma Limited's Morpeth, UK facility from 3rd September, 2026 to 11th September, 2026. At the conclusion of the inspection, the US FDA issued a Form-483, with 7 observations. These observations are related to enhancement in our practices, procedures and documentation. The Company is diligently addressing these observations and is preparing a detailed response for submission to the US FDA within the stipulated timeline. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations. This is for your information and records. Thank you. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com